Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy, Edward Vincent Loftus, Jr

Research output: Contribution to journalReview article

69 Citations (Scopus)

Abstract

In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

Original languageEnglish (US)
Pages (from-to)837-855
Number of pages19
JournalGastroenterology Clinics of North America
Volume35
Issue number4
DOIs
StatePublished - Dec 2006

Fingerprint

Biological Factors
Inflammatory Bowel Diseases
Safety
Histoplasmosis
Opportunistic Infections
Demyelinating Diseases
Lymphoma
Therapeutics
Odds Ratio
Infliximab

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases. / Reddy, Jagadeshwar G.; Loftus, Jr, Edward Vincent.

In: Gastroenterology Clinics of North America, Vol. 35, No. 4, 12.2006, p. 837-855.

Research output: Contribution to journalReview article

@article{2d342a83e2ee471c8bc058db38306fd5,
title = "Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases",
abstract = "In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.",
author = "Reddy, {Jagadeshwar G.} and {Loftus, Jr}, {Edward Vincent}",
year = "2006",
month = "12",
doi = "10.1016/j.gtc.2006.09.008",
language = "English (US)",
volume = "35",
pages = "837--855",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

AU - Reddy, Jagadeshwar G.

AU - Loftus, Jr, Edward Vincent

PY - 2006/12

Y1 - 2006/12

N2 - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

AB - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

UR - http://www.scopus.com/inward/record.url?scp=33751334334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751334334&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2006.09.008

DO - 10.1016/j.gtc.2006.09.008

M3 - Review article

VL - 35

SP - 837

EP - 855

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 4

ER -